AMI Pharm's AYP-101 Enters Phase 3 Redefining Injectable Fat Reduction for Patient Comfort AMI Pharm has announced the entry of its lead candidate AYP-101 into a pivotal Phase 3 study aimed at injectable fat reduction, focusing on patient comfort.

AMI Pharm's AYP-101 Enters Phase 3 Redefining Injectable Fat Reduction for Patient Comfort #South_Korea #Seoul #AMI_Pharm #AYP-101 #Injectable_Medication